07 July 2023
HealthBeacon plc
Director/PDMR Shareholding - Update
Dublin, Ireland - 07 July 2023: HealthBeacon plc (HBCN.ID) ("HealthBeacon" or "the Company"), a digital therapeutics company that develops products for managing injectable medications for patients in the home, today announces an update to correct the RNS of July 5th last. Jim Joyce, Chief Executive Officer and Co-Founder, has purchased 10,800 ordinary shares at a price of €1.86. Following this purchase Jim Joyce holds 1,844,107 shares representing 10.92% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.
Notification - of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them
This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
| a) |
Name |
Jim Joyce |
||||
| 2 |
Reason for the notification |
|||||
| a) |
Position/status |
Person discharging managerial responsibility - Chief Executive Officer |
||||
| b) |
Initial Notification Amendment |
Initial notification |
||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
| a) |
Name |
HealthBeacon plc |
||||
| b) |
LEI |
635400DZJITFJMT8T166 |
||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
| a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of €0.0025 each ("HealthBeacon Shares")
IE00014QAJZ5 |
||||
| b) |
Nature of the transaction |
Purchase of HealthBeacon Shares |
||||
| c) |
Price(s) and volume(s) |
|
||||
| d) |
Aggregated information - Aggregated volume - Price |
10,800
€1.86
|
||||
| e) |
Date of the transaction |
04 July 2023 |
||||
| f) |
Place of the transaction |
Euronext Growth Market Dublin |
||||
| g) |
Additional Information |
N/A |
||||
| Enquiries: |
|
| HealthBeacon: Lar Malone
|
Investor.Relations@HealthBeacon.com |
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Paul Clifford |
+353 (0) 87 327 2161 |
About HealthBeacon plc
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.